The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Your mother and father will not get the compassion and care when they call for medical help . It will not be available. Your family physician was financially forced to leave.
It is important to understand that geographic placement of these clinics is important. I think these clinics will continue to pop up until the industry feels out exactly where the market is. We are located in the southwest suburbs of Chicago, and there are many of these clinics which are...
Pfizer has tentatively agreed to partner with Taisho to develop and commercialize the new schizophrenia drug TS-032 outside Japan. This move may support Pfizer’s efforts to expand its share in the antipsychotic market beyond Geodon.
FDA has recently approved once-daily Seroquel XR for maintenance treatment of adult schizophrenia patients. Risk of relapse and recurrence of acute psychotic symptoms were 84% less in patients receiving Seroquel XR vs. placebo.
Lilly is currently leader in Psychiatry with 4 active medications with great marketing for Psychiatry and Primary care physician. New compound that has a unique mechanism on Metabotropic Glutamate 2/3 Receptors, can work on Schizophrenia and other Psychiatric diagnosis. This is great opportunity...
Acetlion recently reported that Almorexant, a selective orexin receptor antagonist, dose-dependently increased total sleep time in primary insomniacs when compared to placebo.
Evista sales may improve due to the FDA approval for both prevention of invasive breast cancer and osteoporosis but the increase is likely to be very modest. It has advantages over tamoxifen in that Evista does not cause endometrial hyperplasia or cancer of the uterus, however it still carries...
Eli Lilly reported that the prodrug mGluR2/3 agonist LY2140023 met all end points in a randomized, three-armed, double-blind, placebo controlled, 4-week proof-of-concept trial that enrolled schizophrenia patients.
The FDA requested more data to prove that Bifeprunox works in schizophrenia patients. This is the second major blow to Wyeth in many weeks after the FDA requested additional trials to approve Pristiq for vasomotor symptoms.